Eterna Therapeutics Inc (ERNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has a cash flow conversion efficiency ratio of -0.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.27 Million) by net assets ($3.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eterna Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Eterna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ERNA current and long-term liabilities for a breakdown of total debt and financial obligations.
Eterna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eterna Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Snipp Interactive Inc
V:SPN
|
0.082x |
|
Palamina Corp
V:PA
|
0.199x |
|
Saraswati Griya Lestari Tbk
JK:HOTL
|
-0.001x |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
-0.061x |
|
MISSION GROUP PLC LS -10
F:M7K
|
N/A |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
-0.070x |
|
Biovica International AB (publ)
ST:BIOVIC-B
|
-0.670x |
|
AEON Biopharma, Inc.
NYSE MKT:AEON
|
0.131x |
Annual Cash Flow Conversion Efficiency for Eterna Therapeutics Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Eterna Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.70 Million | $-15.84 Million | -9.310x | -1.87% |
| 2023-12-31 | $2.23 Million | $-20.41 Million | -9.139x | -427.50% |
| 2022-12-31 | $12.11 Million | $-20.98 Million | -1.733x | -88.13% |
| 2021-12-31 | $25.50 Million | $-23.49 Million | -0.921x | +12.93% |
| 2020-12-31 | $7.66 Million | $-8.10 Million | -1.058x | -296.24% |
| 2019-12-31 | $5.09 Million | $2.74 Million | 0.539x | +173.13% |
| 2018-12-31 | $6.92 Million | $1.36 Million | 0.197x | +98.99% |
| 2017-12-31 | $5.54 Million | $549.00K | 0.099x | +1654.00% |
| 2016-12-31 | $4.07 Million | $23.00K | 0.006x | +100.52% |
| 2015-12-31 | $3.85 Million | $-4.18 Million | -1.086x | -85.85% |
| 2014-12-31 | $10.92 Million | $-6.38 Million | -0.584x | -460.25% |
| 2013-12-31 | $9.20 Million | $1.49 Million | 0.162x | -40.59% |
| 2012-12-31 | $7.89 Million | $2.16 Million | 0.273x | +202.14% |
| 2011-12-31 | $6.35 Million | $574.00K | 0.090x | -69.79% |
| 2010-12-31 | $9.46 Million | $2.83 Million | 0.299x | +12.59% |
| 2009-12-31 | $9.42 Million | $2.50 Million | 0.266x | +100.69% |
| 2007-12-31 | $15.57 Million | $-604.00 Million | -38.798x | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more